Navigation Links
Researchers find relief for chronic pain
Date:1/22/2008

Researchers in the Department of Medicine and Department of Neurosciences at Mount Sinai School of Medicine have discovered that chronic pain can be successfully treated with novel targeted gene therapy. In an effort to find a more effective treatment for chronic pain, researchers at Mount Sinai developed a gene therapy technique that simulates the pain-killing effect of opiate drugs. In the new study Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain published in the January 22, 2008 issue of the Proceedings of the National Academy of Sciences (PNAS), researchers suggest that gene therapy for pain might in the future become a treatment alternative for patients with severe chronic pain.

Fifty million Americans suffer from chronic pain. Chronic pain patients often do not experience satisfactory pain relief from available treatments due to poor efficacy or intolerable side effects like extreme sleepiness, mental clouding, and hallucinations, said Dr. Andreas Beutler, MD, principal investigator of the study and Assistant Professor of Medicine/ Hematology And Medical Oncology at Mount Sinai School of Medicine.

Mount Sinai researchers designed a viral vector to carry the prepro-b-endorphin gene into primary sensory neurons in order to activate opiate receptors selectively, in a rat model. The agents were delivered directly into the spinal fluid of rats via a lumbar puncture, or spinal tap with only one injection. Results showed that the rats remained symptom-free for an extended period of time.

Our research found that treating chronic pain with Adeno-Associated Virus vector-based gene therapy allows for pain relief for more than three months after a single injection, targeting selectively the pain gate. The technique worked successfully with opioid- and non-opioid therapeutic genes, said Dr. Beutler. Targeted gene therapy will likely avoid the unwanted side effects associated with opioid painkillers such as morphine. Based on our findings, this targeted gene therapy via lumbar puncture appears to be a promising candidate for bench-to-bedside research that might ultimately be tested in patients with intractable chronic pain, e.g., to help patients suffering from severe pain due to advanced cancer.


'/>"/>

Contact: Mount Sinai Newsroom
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers propose consumers buy yearly drug licenses as new way to pay for prescriptions
2. Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
3. DOE awards supercomputing time to UCSD, SDSC researchers
4. Argonnes Blue Gene/P to host large cadre of INCITE researchers
5. Researchers Hone in on Cancer Stem Cells for Melanoma
6. Anyone can save a life: Penn researchers lead national efforts to improve CPR quality
7. Researchers find new way to block destructive rush of immune cells
8. U of M researchers create beating heart in laboratory
9. Researchers challenge previous findings regarding widely used asthma treatment
10. UT Health Science Center researchers decoding saliva to detect breast cancer
11. Protein power: Researchers trigger insulin production in diabetic mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... ... for and by physicians, announced today the launch of a free, public-facing tool ... Via Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, ...
(Date:3/28/2017)... CT (PRWEB) , ... March 28, 2017 , ... ... devices, announces today that the University of Pittsburgh Medical Center (UPMC) will acquire ... and Western Pennsylvania. , The program, developed in association with efforts by the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Usually, the ... the daily wardrobe. However, for those self-conscious about a double chin, this means more ... the ideal solution. , “For most people, a double chin is undesirable,” Dr. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... ... 28, 2017 , ... Qualidigm , the mission-driven national ... a new, more expansive office space in order to accommodate its growing number ... office building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)...  A recent study at Shriners Hospitals for Children ... the country dedicated to the treatment of pediatric burns ... the Surfacide Helios ® UV-C Disinfection System is ... pathogens not killed by the EVS (manual) cleaning process ... Burn Association,s 49th Annual Meeting in Boston ...
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: ... it intends to offer shares of common stock in ... statement on file with the Securities and Exchange Commission ... other conditions, and there can be no assurance as ... or as to the actual size or terms of ...
(Date:3/27/2017)... Germany , March 27, 2017 ... over 7,000 attendees and more than 600 exhibitors ... and discover opportunities and solutions that will advance ... 6 April 2017 at the Messe Stuttgart, ... the preeminent medical technology platform showcasing the key ...
Breaking Medicine Technology: